Streetbeat News

Revenues

FMC

FMC Corporation has set new three-year rolling financial goals targeting 2026 revenues of $5.5B-$6.0B and adjusted EBITDA of $1.3B-$1.5B.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 12:37 pm

TWST

Twist Bioscience forecasts FY24 revenue to be between $285M-$290M, which is below the consensus estimate of $298.79M. The company also anticipates a gross margin of approximately 39%-40% for the same period.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 12:36 pm

FMC

FMC Corporation has released its preliminary outlook for 2024, projecting revenues between $4.65 billion and $4.85 billion, adjusted EBITDA of $1.025 billion to $1.125 billion, and a free cash flow conversion rate of over 100 percent.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 12:35 pm

YTRA

Yatra Online reported a 10.2% year-over-year increase in Total Gross Bookings, reaching $210.9 million. This includes revenue from Air Ticketing, Hotels and Packages, and Other Services.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 12:34 pm

YTRA

Yatra Online (NASDAQ: YTRA) reported a significant decrease in sales for Q2, with $11.40 million in sales compared to $18.63 million in the same quarter last year, marking a 38.78% decline.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 12:32 pm

DXLG

Destination XL Group (DXLG) has revised its full-year sales forecast to $520.0M-$530.0M, down from the previous range of $535.0M-$545.0M, and below the analyst estimate of $534.90M. The company also adjusted its EPS guidance to $0.39-$0.46, which is lower than both the prior view of $0.45-$0.53 and the analyst estimate of $0.54.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 12:30 pm

AFIB

BDX

EGRX

VTYX

The article highlights four health care stocks considered oversold based on their Relative Strength Index (RSI) values, suggesting potential buying opportunities. Eagle Pharmaceuticals (EGRX) delays Q3 results, Acutus Medical (AFIB) announces restructuring, Becton, Dickinson (BDX) reports mixed results with lower guidance, and Ventyx Biosciences (VTYX) posts in-line loss with upcoming pipeline updates.

Portfolio Pulse from Lisa Levin

November 17, 2023 | 12:26 pm

CINT

CI&T forecasts a revenue growth of 4.0%-5.0% for the fiscal year 2023, with an expected adjusted EBITDA margin of at least 19%.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 12:23 pm

CINT

CI&T expects to report Q4 revenue in the range of R$519 million to R$540 million.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 12:22 pm

CINT

CI&T reported Q3 sales of $108.40M, which fell short of the $109.11M estimate. The company also reported earnings per share (EPS) of $0.05 for the quarter.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 12:19 pm